These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 25673514)

  • 1. Building the Human Vaccines Project: strategic management recommendations and summary report of the 15-16 July 2014 business workshop.
    Schenkelberg T; Kieny MP; Bianco AE; Koff WC
    Expert Rev Vaccines; 2015 May; 14(5):629-36. PubMed ID: 25673514
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sustaining GAVI-supported vaccine introductions in resource-poor countries.
    Zuber PL; El-Ziq I; Kaddar M; Ottosen AE; Rosenbaum K; Shirey M; Kamara L; Duclos P
    Vaccine; 2011 Apr; 29(17):3149-54. PubMed ID: 21354249
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decoding the human immune system to transform the future of global disease prevention and control.
    Koff WC; Schenkelberg T
    Expert Rev Vaccines; 2016 Oct; 15(10):1235-6. PubMed ID: 27010379
    [No Abstract]   [Full Text] [Related]  

  • 4. Strengthening vaccination policies in Latin America: an evidence-based approach.
    Tapia-Conyer R; Betancourt-Cravioto M; Saucedo-Martínez R; Motta-Murguía L; Gallardo-Rincón H
    Vaccine; 2013 Aug; 31(37):3826-33. PubMed ID: 23357196
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Partnering for Vaccine Emerging Markets--Berlin, June 10-11, 2013: balancing vaccine quality, capacity, and cost-of-goods in emerging markets.
    Onraedt A
    Hum Vaccin Immunother; 2013 Sep; 9(9):2022-4. PubMed ID: 23966097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An evaluation of South Africa's public-private partnership for the localisation of vaccine research, manufacture and distribution.
    Walwyn DR; Nkolele AT
    Health Res Policy Syst; 2018 Mar; 16(1):30. PubMed ID: 29587777
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Are good intentions putting the vaccination ecosystem at risk?
    Watson M; Faron de Goër E
    Hum Vaccin Immunother; 2016 Sep; 12(9):2469-74. PubMed ID: 27269046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccines: from valuation to resource allocation.
    Bloom DE; Madhavan G
    Vaccine; 2015 Jun; 33 Suppl 2():B52-4. PubMed ID: 26022569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preventing infectious diseases for healthy ageing: The VITAL public-private partnership project.
    Van Baarle D; Bollaerts K; Del Giudice G; Lockhart S; Luxemburger C; Postma MJ; Timen A; Standaert B;
    Vaccine; 2020 Aug; 38(37):5896-5904. PubMed ID: 32713682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. European Union vaccine research--an overview.
    Sautter J; Olesen OF; Bray J; Draghia-Akli R
    Vaccine; 2011 Sep; 29(39):6723-7. PubMed ID: 21195799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contribution of the GAVI Alliance to improving health and reducing poverty.
    Lob-Levyt J
    Philos Trans R Soc Lond B Biol Sci; 2011 Oct; 366(1579):2743-7. PubMed ID: 21893535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Delivering the promise of the Decade of Vaccines: opportunities and challenges in the development of high quality new vaccines.
    Keith JA; Agostini Bigger L; Arthur PA; Maes E; Daems R
    Vaccine; 2013 Apr; 31 Suppl 2():B184-93. PubMed ID: 23598480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Second National Immunization Congress 2010: addressing vaccine financing for the future in the US.
    Shen AK; Sobzcyk E; Buchanan A; Wu L; Duggan-Goldstein S
    Hum Vaccin; 2011 Jan; 7(1):12-8. PubMed ID: 21178397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Towards a European strategy for medicines research (2014-2020): The EUFEPS position paper on Horizon 2020.
    Gaspar R; Aksu B; Cuine A; Danhof M; Takac MJ; Linden HH; Link A; Muchitsch EM; Wilson CG; Ohrngren P; Dencker L
    Eur J Pharm Sci; 2012 Dec; 47(5):979-87. PubMed ID: 23046836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current barriers, challenges and opportunities for the development of effective STI vaccines: point of view of vaccine producers, biotech companies and funding agencies.
    Dodet B
    Vaccine; 2014 Mar; 32(14):1624-9. PubMed ID: 23994377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Technology transfer in human vaccinology: a retrospective review on public sector contributions in a privatizing science field.
    Hendriks J
    Vaccine; 2012 Sep; 30(44):6230-40. PubMed ID: 22902679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The ProVac initiative and evolving decision support.
    Sanderson CF
    Vaccine; 2015 May; 33 Suppl 1():A8-10. PubMed ID: 25919181
    [No Abstract]   [Full Text] [Related]  

  • 18. Understanding the human immune system in the 21st century: the Human Immunology Project Consortium.
    Poland GA; Quill H; Togias A
    Vaccine; 2013 Jun; 31(28):2911-2. PubMed ID: 23648045
    [No Abstract]   [Full Text] [Related]  

  • 19. The need for new vaccines.
    Taylor K; Nguyen A; Stéphenne J
    Vaccine; 2009 Dec; 27 Suppl 6():G3-8. PubMed ID: 20006137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of health economic analyses in vaccine decision making.
    Black S
    Vaccine; 2013 Dec; 31(51):6046-9. PubMed ID: 23968768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.